title: Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells.
abstract: The hallmark of chronic myeloid leukemia (CML) is the presence of the bcr-abl oncogene, which is associated with transforming ability and an intrinsic resistance to induction of apoptosis by genotoxic agents. Arachidonic acid (AA), a biologically active fatty acid, plays a crucial role as a mediator of signaling pathways involved in cell proliferation and survival. In this study, we investigated the potential role of AA as a proapoptotic agent in CML. Pretreatment of human CML isolated progenitor cells with AA (100 microM for 18 h) induced 71-75% inhibition of in vitro colony formation of granulocyte-macrophage colony-forming units, multilineage colony-forming units, and erythroid burst-forming units. This inhibition was significantly greater than the effect on normal progenitor cells (19-39% growth inhibition of erythroid burst-forming units, multilineage colony-forming units, and granulocyte-macrophage colony-forming units). AA also inhibited growth of the bcr-abl-transformed cell line H7.bcr-abl A54. In contrast, a minimal effect of AA on inhibition of cell growth was observed in the parental nontransformed NSF/N1.H7 cell line. The antiproliferative effect of AA was associated with apoptosis. Gamma-linolenic acid, a precursor of AA, also inhibited cell growth, whereas other unsaturated and saturated fatty acids had no effect. Pharmacological inhibition of cyclooxygenase, lipooxygenase, and cytochrome P450 monooxygenase enzymes prior to exposure to AA did not rescue cells from the inhibitory effect of AA. Moreover, 5,8,11,14-eicosatetraynoic acid, a nonmetabolizable arachidonate analogue, also inhibited cell growth, suggesting that the effect of AA did not require further metabolism. Treatment with antioxidants prior to stimulation with AA was also ineffective in preventing its antiproliferative effect. Thus, AA inhibited proliferation of CML cells by inducing apoptotic cell death. The signaling mechanisms of AA-induced inhibition of cell growth appeared to be independent of its conversion into eicosanoids or free radical generation.
authors.affiliation: Signal Transduction Laboratory, Methodist Research Institute, Indianapolis, Indiana 46202, USA. mrizzo@clarian.com
authors.forename: M T
authors.initials: MT
authors.lastname: Rizzo
authors.forename: E
authors.initials: E
authors.lastname: Regazzi
authors.forename: D
authors.initials: D
authors.lastname: Garau
authors.forename: L
authors.initials: L
authors.lastname: Akard
authors.forename: M
authors.initials: M
authors.lastname: Dugan
authors.forename: H S
authors.initials: HS
authors.lastname: Boswell
authors.forename: V
authors.initials: V
authors.lastname: Rizzoli
authors.forename: C
authors.initials: C
authors.lastname: Carlo-Stella
mesh_terms: D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology; D000328:Adult; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D016718:Arachidonic Acid / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000473:pathology; D002109:Caffeic Acids / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D003114:Colony-Forming Units Assay; D015672:Erythroid Precursor Cells / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D005260:Female; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000473:pathology* / Q000648:ultrastructure; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D007654:Ketoconazole / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D008297:Male; D009637:Masoprocol / Q000494:pharmacology; D051379:Mice; D008875:Middle Aged; D014407:Tumor Cells, Cultured
chemical_list: D000975:Antioxidants; D002109:Caffeic Acids; D015117:5,8,11,14-Eicosatetraynoic Acid; D016718:Arachidonic Acid; D009637:Masoprocol; D007654:Ketoconazole; C040048:caffeic acid; D007213:Indomethacin